BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis. 2017;20:859-869. [PMID: 28160426 DOI: 10.1111/1756-185x.13010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Licata A, Minissale MG, Distefano M, Montalto G. Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know? GastroHep 2021;3:121-30. [PMID: 34149320 DOI: 10.1002/ygh2.455] [Reference Citation Analysis]
2 Baroiu L, Dumitru C, Iancu A, Leșe AC, Drăgănescu M, Baroiu N, Anghel L. COVID-19 impact on the liver. World J Clin Cases 2021; 9(16): 3814-3825 [PMID: 34141738 DOI: 10.12998/wjcc.v9.i16.3814] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Tharmarajah E, Buazon A, Patel V, Hannah JR, Adas M, Allen VB, Bechman K, Clarke BD, Nagra D, Norton S, Russell MD, Rutherford AI, Yates M, Galloway JB. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. J Infect 2021;82:178-85. [PMID: 33745918 DOI: 10.1016/j.jinf.2021.03.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Elnaggar M, Abomhya A, Elkhattib I, Dawoud N, Doshi R. COVID-19 and liver diseases, what we know so far. World J Clin Cases 2022; 10(13): 3969-3980 [DOI: 10.12998/wjcc.v10.i13.3969] [Reference Citation Analysis]
5 Idalsoaga F, Ayares G, Arab JP, Díaz LA. COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence. J Clin Transl Hepatol 2021;9:760-8. [PMID: 34722191 DOI: 10.14218/JCTH.2020.00140] [Reference Citation Analysis]
6 Rando HM, Wellhausen N, Ghosh S, Lee AJ, Dattoli AA, Hu F, Byrd JB, Rafizadeh DN, Lordan R, Qi Y, Sun Y, Brueffer C, Field JM, Ben Guebila M, Jadavji NM, Skelly AN, Ramsundar B, Wang J, Goel RR, Park Y, Boca SM, Gitter A, Greene CS; COVID-19 Review Consortium Vikas Bansal, John P. Barton, Simina M. Boca, Joel D. Boerckel, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Daniel S. Himmelstein, Fengling Hu, Nafisa M. Jadavji, Jeremy P. Kamil, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D’Agostino McGowan, Amruta Naik, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Vincent Rubinetti, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Yusha Sun, Gregory L. Szeto, Ryan Velazquez, Jinhui Wang, Nils Wellhausen. Identification and Development of Therapeutics for COVID-19. mSystems 2021;:e0023321. [PMID: 34726496 DOI: 10.1128/mSystems.00233-21] [Reference Citation Analysis]
7 Reddy KR. SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections. Clin Liver Dis (Hoboken) 2020;15:191-4. [PMID: 32489654 DOI: 10.1002/cld.970] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
8 Kardani K, Bolhassani A, Kardani M, Agi E; Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran, Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran. Correlation of SARS-CoV-2 Infection with Hepatitis and Liver Disorders. JoMMID 2021;9:122-32. [DOI: 10.52547/jommid.9.3.122] [Reference Citation Analysis]
9 Ridruejo E, Soza A. The liver in times of COVID-19: What hepatologists should know. Ann Hepatol. 2020;19:353-358. [PMID: 32425991 DOI: 10.1016/j.aohep.2020.05.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
10 Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 mo of the pandemic. JHEP Rep. 2020;2:100169. [PMID: 32835190 DOI: 10.1016/j.jhepr.2020.100169] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 21.0] [Reference Citation Analysis]
11 Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2:100113. [PMID: 32289115 DOI: 10.1016/j.jhepr.2020.100113] [Cited by in Crossref: 203] [Cited by in F6Publishing: 201] [Article Influence: 101.5] [Reference Citation Analysis]
12 Wang H, Zhang N, Fang K, Chang X. 2-Deoxy-D-glucose Alleviates Collagen-Induced Arthritis of Rats and Is Accompanied by Metabolic Regulation of the Spleen and Liver. Front Immunol 2021;12:713799. [PMID: 34539643 DOI: 10.3389/fimmu.2021.713799] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sonneveld MJ, Murad SD, van der Eijk AA, de Man RA. Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab. ACG Case Rep J. 2019;6:e00243. [PMID: 32042838 DOI: 10.14309/crj.0000000000000243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
14 Yip TC, Gill M, Wong GL, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int 2022. [PMID: 35235148 DOI: 10.1007/s12072-022-10306-x] [Reference Citation Analysis]
15 Zhou Q, Zhang Q, Wang K, Huang T, Deng S, Wang Y, Cheng C. Anti-rheumatic Drug-induced Hepatitis B Virus Reactivation and Preventive Strategies for Hepatocellular Carcinoma. Pharmacol Res 2022;:106181. [PMID: 35301112 DOI: 10.1016/j.phrs.2022.106181] [Reference Citation Analysis]
16 Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med 2021;10:2564. [PMID: 34200522 DOI: 10.3390/jcm10122564] [Reference Citation Analysis]
17 Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
18 Chang Y, Jeong SW, Jang JY. Hepatitis B Virus Reactivation Associated With Therapeutic Interventions. Front Med (Lausanne) 2021;8:770124. [PMID: 35096867 DOI: 10.3389/fmed.2021.770124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 da Cunha MR, Rodrigues IC, Trigueiros F, Freitas LC, Braz S, Cota Medeiros F. A Case of Severe Acute Respiratory Syndrome Coronavirus 2 Treatment With Remdesivir in a Hepatitis C-Coinfected Patient Resulting in Temporary Viral Control and Posttreatment Flare. Open Forum Infect Dis 2021;8:ofab100. [PMID: 33880393 DOI: 10.1093/ofid/ofab100] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Varona Pérez J, Rodriguez Chinesta J. Risk of hepatitis B reactivation associated with treatment against SARS-CoV-2 (COVID-19) with corticosteroids. Revista Clínica Española (English Edition) 2020;220:535-6. [DOI: 10.1016/j.rceng.2020.04.006] [Reference Citation Analysis]
21 APASL Covid-19 Task Force. Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14:415-428. [PMID: 32447721 DOI: 10.1007/s12072-020-10054-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
22 Roodenrijs NMT, Hamar A, Kedves M, Nagy G, van Laar JM, van der Heijde D, Welsing PMJ. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open 2021;7:e001512. [PMID: 33419871 DOI: 10.1136/rmdopen-2020-001512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
23 Rahban M, Stanek A, Hooshmand A, Khamineh Y, Ahi S, Kazim SN, Ahmad F, Muronetz V, Samy Abousenna M, Zolghadri S, Saboury AA. Infection of Human Cells by SARS-CoV-2 and Molecular Overview of Gastrointestinal, Neurological, and Hepatic Problems in COVID-19 Patients. J Clin Med 2021;10:4802. [PMID: 34768321 DOI: 10.3390/jcm10214802] [Reference Citation Analysis]
24 Garrido I, Liberal R, Macedo G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52:267-275. [PMID: 32402090 DOI: 10.1111/apt.15813] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 31.0] [Reference Citation Analysis]
25 Pandolfi F, Franza L, Carusi V, Altamura S, Andriollo G, Nucera E. Interleukin-6 in Rheumatoid Arthritis. Int J Mol Sci 2020;21:E5238. [PMID: 32718086 DOI: 10.3390/ijms21155238] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
26 Sweed D, Abdelsameea E, Khalifa EA, Abdallah H, Moaz H, Moaz I, Abdelsattar S, Abdel-Rahman N, Mosbeh A, Elmahdy HA, Sweed E. SARS-CoV-2-associated gastrointestinal and liver diseases: what is known and what is needed to explore. Egypt Liver J 2021;11:64. [PMID: 34777871 DOI: 10.1186/s43066-021-00123-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Anirvan P, Bharali P, Gogoi M, Thuluvath PJ, Singh SP, Satapathy SK. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome — what we know so far. World J Hepatol 2020; 12(12): 1182-1197 [PMID: 33442447 DOI: 10.4254/wjh.v12.i12.1182] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
28 Gupta M, Manek G, Dombrowski K, Maiwall R. Newer developments in viral hepatitis: Looking beyond hepatotropic viruses. World J Meta-Anal 2021; 9(6): 522-542 [DOI: 10.13105/wjma.v9.i6.522] [Reference Citation Analysis]
29 Su HY, Hsu YC. Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives . World J Clin Cases 2021; 9(13): 2951-2968 [PMID: 33969082 DOI: 10.12998/wjcc.v9.i13.2951] [Reference Citation Analysis]
30 Ali FEM, Mohammedsaleh ZM, Ali MM, Ghogar OM. Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. World J Gastroenterol 2021; 27(15): 1531-1552 [PMID: 33958841 DOI: 10.3748/wjg.v27.i15.1531] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Shady A, Singh AP, Gbaje E, Oliva M, Golden-Espinal S, Macciola D, Soto D, Eddy WE, Adkoli A, Bergasa NV. Characterization of Patients with COVID-19 Admitted to a Community Hospital of East Harlem in New York City. Cureus 2020;12:e9836. [PMID: 32953343 DOI: 10.7759/cureus.9836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Foerster J, Molęda A. Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine. Vaccines (Basel) 2019;7:E20. [PMID: 30759882 DOI: 10.3390/vaccines7010020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Xiang TD, Zheng X. Interaction between hepatitis B virus and SARS-CoV-2 infections. World J Gastroenterol 2021; 27(9): 782-793 [PMID: 33727770 DOI: 10.3748/wjg.v27.i9.782] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Ehrenstein B. [Interpretation of tuberculosis and hepatitis screening before immunosuppressive treatment]. Z Rheumatol 2018;77:493-507. [PMID: 29947949 DOI: 10.1007/s00393-018-0488-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
35 Dufour JF, Marjot T, Becchetti C, Tilg H. COVID-19 and liver disease. Gut 2022:gutjnl-2021-326792. [PMID: 35701093 DOI: 10.1136/gutjnl-2021-326792] [Reference Citation Analysis]
36 Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021;. [PMID: 33387124 DOI: 10.1007/s10620-020-06725-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Zaky S, Alboraie M, El Badry M, Metwally MA, Abdelaziz A, Fouad Y, Abd-Elsalam S, Mahmoud A, Shiha G, Baki AA, El Kassas M, Esmat G. Management of liver disease patients in different clinical situations during COVID-19 pandemic. Egypt Liver J 2021;11:21. [PMID: 34777868 DOI: 10.1186/s43066-021-00091-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Varona Pérez J, Rodriguez Chinesta JM. [Risk of hepatitis B reactivation associated with treatment against SARS-CoV-2 (COVID-19) with corticosteroids]. Rev Clin Esp (Barc) 2020;220:534-6. [PMID: 32372768 DOI: 10.1016/j.rce.2020.04.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]